首页 | 本学科首页   官方微博 | 高级检索  
检索        

卡培他滨单药或联合方案治疗乳腺癌骨转移的临床疗效观察
引用本文:张亚峰,王鹏.卡培他滨单药或联合方案治疗乳腺癌骨转移的临床疗效观察[J].实用癌症杂志,2017(12):2045-2048.
作者姓名:张亚峰  王鹏
作者单位:714000,陕西省渭南市中心医院
摘    要:目的 探讨卡培他滨单药或联合伊班膦酸钠方案治疗乳腺癌骨转移的临床疗效.方法 选择乳腺癌骨转移患者106例作为研究对象,根据随机信封抽签原则分为观察组与对照组各53例,对照组给予卡培他滨单药治疗,观察组在对照组治疗的基础上联用伊班膦酸钠治疗.结果 治疗后观察组与对照组总有效率分别为86.8%和69.8%,观察组总有效率明显高于对照组(P<0.05).观察组随访1年、2年、3年的生存率分别为90.6%、77.4%和49.1%,都明显高于对照组的79.2%、50.9%和20.8%(P<0.05).治疗后观察组与对照组的骨痛NRS评分分别为(1.43±0.84)分和(2.53±1.21)分,都明显低于治疗前的(6.93±2.01)分和(6.91±2.13)分(P<0.05),治疗后观察组的骨痛NRS评分也明显低于对照组(P<0.05).结论 相对于卡培他滨单药方案,卡培他滨联合伊班膦酸钠方案治疗乳腺癌骨转移能有效降低骨痛,提高治疗疗效,从而延长患者的生存期,有很好的应用价值.

关 键 词:卡培他滨  伊班膦酸钠  乳腺癌  骨转移  生存期

Clinical Efficacy of Capecitabine Monotherapy or Combination with Chemotherapy in the Treatment of Breast Cancer with Bone Metastasis
ZHANG Yafeng,WANG Peng.Clinical Efficacy of Capecitabine Monotherapy or Combination with Chemotherapy in the Treatment of Breast Cancer with Bone Metastasis[J].The Practical Journal of Cancer,2017(12):2045-2048.
Authors:ZHANG Yafeng  WANG Peng
Abstract:Objective To investigate the clinical efficacy of capecitabine monotherapy or combination with ibandronate in the treatment of breast cancer with bone metastasis. Methods 106 cases of breast cancer with bone metastasis were selected as the research object,all the cases were divided into the observation group and the control group,with 53 cases in each group,ac-cording to the random draw envelope,the control group was given capecitabine monotherapy,the observation group was given the ibandronate treatment based on the the control group. Results After treatment,the total effective rates of the observation group and the control group were 86. 8% and 69. 8%,respectively. The total effective rate of the observation group was significantly higher than that of the control group (P<0. 05). 1-,2-,3-year survival rates of the observation group were 90. 6%,77. 4% and 49. 1%,respectively,which were significantly higher than those of the control group of 79. 2%,50. 9%,and 20. 8%(P<0. 05). After treatment,the NRS pain scores in the observation group and the control group were 1. 43 ± 0. 84 points and 2. 53 ± 1. 21 points,which were significantly lower than those before treatment of 6.93 ±2.01 points and 6.91 ±2.13points (P<0.05),the NRS pain score in the observation group after treatment was significantly lower than the control group (P<0. 05). Conclusion Compared with capecitabine monotherapy,capecitabine combined with ibandronate in the treatment of breast cancer with bone me-tastasis can effectively reduce bone pain,improve curative effect,so as to prolong the survival time of patients,and it has good ap-plication values.
Keywords:Capecitabine  Ibandronate  Breast cancer  Bone metastasis  Survival
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号